STOCK TITAN

Summit Therapeutics announces Phase III HARMONi-10 trial

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Summit Therapeutics Inc. announced a new global Phase III HARMONi-10 trial of ivonescimab in locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC). The study will compare ivonescimab with durvalumab as consolidation therapy for patients whose disease has not progressed following platinum-based concurrent chemoradiation. Progression-free survival is the primary endpoint. The trial is multi-regional, open-label and potentially registration-enabling; Summit says it is its sixth sponsored Phase III study of ivonescimab and fourth in NSCLC. The company describes durvalumab following curative-intent chemoradiation as a current standard of care in this setting.

Global clinical trial site activations are expected to begin in the fourth quarter of 2026. Ivonescimab is investigational and not approved in Summit’s license territories, including the United States and Europe; the company says it first received marketing authorization in China in May 2024. Summit reports that five Phase III ivonescimab studies have read out, all with positive data. Its definition of a positive study requires at least one prespecified primary endpoint to achieve statistically significant benefit according to the study protocol or statistical analysis plan.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Trial phase Phase III HARMONi-10 evaluates ivonescimab in NSCLC.
Summit-sponsored ivonescimab Phase III study count Sixth HARMONi-10 is Summit’s sixth sponsored Phase III study of ivonescimab.
Summit-sponsored Phase III NSCLC study count Fourth HARMONi-10 is Summit’s fourth sponsored Phase III study of ivonescimab in NSCLC.
Global site activation timing Fourth quarter of 2026 Expected start of HARMONi-10 site activations.
Phase III ivonescimab studies read out 5 Summit reports all five had positive data under its stated definition of a positive study.
consolidation therapy medical
"as consolidation therapy in patients with locally advanced"
progression-free survival medical
"primary endpoint of the study is progression-free survival"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
PD-1 x VEGF bispecific antibody medical
"an investigational, novel PD-1 x VEGF bispecific antibody"
A PD-1 x VEGF bispecific antibody is a specialized medicine designed to target two different factors involved in disease growth at the same time. Think of it as a dual-purpose tool that can block signals preventing the immune system from attacking tumors and also cut off the blood supply that tumors need to grow. For investors, such therapies represent innovative approaches that could potentially improve treatment outcomes and market potential in the healthcare industry.
platinum-based concurrent chemoradiation medical
"following platinum-based concurrent chemoradiation therapy"
open-label technical
"a multi-regional, open-label, potentially registration-enabling Phase III clinical trial"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
tumor microenvironment medical
"higher expression of both PD-1 and VEGF in tumor tissue and the tumor microenvironment"
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is SMMT’s HARMONi-10 trial testing?

It will compare ivonescimab with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC whose disease has not progressed following platinum-based concurrent chemoradiation.

Who can participate in SMMT’s HARMONi-10 trial?

The study is for patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001599298FALSE00015992982026-11-182026-11-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): November 18, 2026
 
Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware001-3686637-1979717
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
601 Brickell Key Drive, Suite 1000, Miami, FL
33131
(Address of Principal Executive Offices)(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: (305) 203-2034
 
Not applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common stock, $0.01 par value per shareSMMTThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 8.01
Other Events.

On November 18, 2026, Summit Therapeutics Inc. issued a press release announcing the planned initiation of the global Phase III HARMONi-10 trial (“HARMONi-10”). HARMONi-10 will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number
Description
99.1
Press Release, dated November 18, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
SUMMIT THERAPEUTICS INC.
Date: November 18, 2026By:/s/ Manmeet S. Soni
Chief Operating Officer, Chief Financial Officer and Director
(Principal Financial Officer)

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurrent Chemoradiation Miami, Florida, November 18, 2026 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC). The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Consolidation therapy, given after a patient has responded to initial treatment, aims to deepen or prolong that response and delay or prevent the cancer from coming back or progressing. HARMONi-10 is Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following HARMONi, HARMONi-3, and HARMONi-7. The study extends Summit’s global clinical development program into the locally advanced, unresectable setting, where durvalumab, following curative-intent chemoradiation, is a current standard of care. “HARMONi-10 is the next bold step in a clinical development program built to change what is possible for people with lung cancer,” said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit. “We are taking ivonescimab head-to-head against standard-of-care PD-L1 therapy in this global Phase III trial, in earlier stage disease, because we believe in its potential and intend to prove it. This is the rigor, ambition, and conviction we have brought to this program from day one.” HARMONi-10 is a multi-regional, open-label, potentially registration-enabling Phase III clinical trial. The primary endpoint of the study is progression-free survival (PFS). Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026. “Patients with unresectable Stage III non-small cell lung cancer endure an intensive course of chemoradiation, and too often their disease still progresses thereafter despite current consolidation therapy,” said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit. “In this curative-intent setting, this is a gap we are determined to close. With PD-1 and VEGF blockade in a single molecule, we believe ivonescimab has the potential to keep the disease from progressing for longer than durvalumab in this setting. We are moving with urgency to activate sites globally and bring ivonescimab to many more people living with lung cancer.” Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024. About Ivonescimab Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti- angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays


 

unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF. This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets. Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso. There are currently 18 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, six of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251). Summit announced the initiation of an additional Phase III trial in NSCLC, HARMONi-10, in November 2026. HARMONi is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI (e.g., osimertinib). HARMONi-3 is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression. The clinical trial is evaluating the two histologies as individual, separately powered cohorts with independent statistical powering. HARMONi-7 is a Phase III clinical trial evaluating ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression. HARMONi-10 is a Phase III clinical trial evaluating ivonescimab compared to durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit’s positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2,


 

HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China. Akeso is actively conducting multiple Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer. Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and its shares are listed on the Nasdaq Global Market (symbol "SMMT"). The company is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK. For more information, please visit https://www.smmttx.comhttps://www.smmttx.com and follow us on X @SMMT_TX. Summit Forward-looking Statements Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At- The-Market equity offering program (“ATM Program”), or the AstraZeneca private placement, the expected proceeds, uses thereof and possibility that the proceeds will not be sufficient to fund operations as long as anticipated, dilution to existing stockholders and potential adverse effects on the market price of the Company’s common stock, including from future sales by AstraZeneca, AstraZeneca’s ownership and contractual rights, including Third Party acquisition participation, registration rights and potential conflicts of interest, the Company’s reliance on third parties for the supply of third party products and other contributions to certain combination clinical trials, the Company’s estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, market, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions


 

with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. Contact Summit Investor Relations: Nathan LiaBraaten Senior Director, Investor Relations Tracy Jones Director, Media & Public Relations investors@smmttx.com media@smmttx.com Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.


 

Filing Exhibits & Attachments

5 documents

Keep reading